BeyondSpring Inc (BYSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BeyondSpring Inc (BYSI) has a cash flow conversion efficiency ratio of 0.236x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.65 Million) by net assets ($-23.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is BeyondSpring Inc's balance sheet to measure how much of total assets are equity-financed.
BeyondSpring Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how BeyondSpring Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BeyondSpring Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
BeyondSpring Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BeyondSpring Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OptimumBank Holdings, Inc.
NASDAQ:OPHC
|
0.016x |
|
Done.ai Group AB
ST:TINGS-B
|
0.009x |
|
CTCBIO Inc
KQ:060590
|
0.079x |
|
Batm Advanced Communications Ltd
TA:BVC
|
-0.054x |
|
Joinsoon Electronics MFG Co Ltd
TWO:3322
|
-0.067x |
|
Minesto AB
ST:MINEST
|
-0.057x |
|
Cybertech Systems And Software Limited
NSE:CYBERTECH
|
0.085x |
|
Amplia Therapeutics Ltd
AU:ATX
|
-0.028x |
Annual Cash Flow Conversion Efficiency for BeyondSpring Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of BeyondSpring Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see BYSI market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-23.99 Million | $-20.02 Million | 0.835x | -27.49% |
| 2024-12-31 | $-14.29 Million | $-16.44 Million | 1.151x | +63.93% |
| 2023-12-31 | $-23.46 Million | $-16.47 Million | 0.702x | -92.50% |
| 2022-12-31 | $-3.01 Million | $-28.15 Million | 9.362x | +514.63% |
| 2021-12-31 | $20.92 Million | $-47.24 Million | -2.258x | -373.93% |
| 2020-12-31 | $91.82 Million | $-43.74 Million | -0.476x | +69.21% |
| 2019-12-31 | $31.13 Million | $-48.16 Million | -1.547x | -136.33% |
| 2018-12-31 | $-9.38 Million | $-39.95 Million | 4.259x | +514.63% |
| 2017-12-31 | $28.04 Million | $-28.80 Million | -1.027x | +7.78% |
| 2016-12-31 | $12.30 Million | $-13.70 Million | -1.114x | -63.72% |
| 2015-12-31 | $9.66 Million | $-6.57 Million | -0.680x | -657.57% |
| 2014-12-31 | $-9.39 Million | $-1.15 Million | 0.122x | -- |
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical t… Read more